Vault-13

STEMPOINT CAPITAL LP

NEW YORK, NY · CIK 1952142 · 13F filing filed 2025-08-14

SEC-registered investment adviser since 2022 · limited partnership

As an employer

$310.6m reported value -0.8% vs Q1 2025
50positions
50.2%in top 10
18 new 16 added 15 reduced 20 sold out vs Q1 2025

Options: 3 call positions ($980.1k notional), 0 put positions (— notional) – listed below, not included above.

Holdings, Q2 2025

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 SYNDAX PHARMACEUTICALS INC COM SNDX SNDX 2,372,634 $22.2m7.15% 7.15% AddedShares held: Q3 2024 1.7m, Q4 2024 2.9m, Q1 2025 1.6m, Q2 2025 2.4m +774.0k +774,040 48.4%
2 IMMUNOVANT INC COM IMVT IMVT 1,300,860 $20.8m6.70% 6.70% AddedShares held: Q3 2024 671.0k, Q4 2024 1.1m, Q1 2025 853.5k, Q2 2025 1.3m +447.4k +447,388 52.4%
3 SCHOLAR ROCK HLDG CORP COM SRRK SRRK 528,115 $18.7m6.02% 6.02% ReducedShares held: Q3 2024 0, Q4 2024 166.3k, Q1 2025 566.2k, Q2 2025 528.1k -38.1k -38,097 -6.7%
4 CENTESSA PHARMACEUTICALS PLC SPONSORED ADS SPONSORED ADS 1,265,672 $16.6m5.35% 5.35% AddedShares held: Q3 2024 83.7k, Q4 2024 642.0k, Q1 2025 593.3k, Q2 2025 1.3m +672.3k +672,337 113.3%
5 MADRIGAL PHARMACEUTICALS INC COM MDGL MDGL 52,694 $15.9m5.13% 5.13% AddedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 40.9k, Q2 2025 52.7k +11.8k +11,758 28.7%
6 MERUS N V COM MRUS MRUS 266,094 $14.0m4.51% 4.51% ReducedShares held: Q3 2024 421.2k, Q4 2024 614.8k, Q1 2025 346.8k, Q2 2025 266.1k -80.7k -80,662 -23.3%
7 ARCELLX INC COMMON STOCK ACLX ACLX 201,452 $13.3m4.27% 4.27% ReducedShares held: Q3 2024 60.1k, Q4 2024 0, Q1 2025 273.8k, Q2 2025 201.5k -72.3k -72,322 -26.4%
8 CIDARA THERAPEUTICS INC COM NEW CDTX CDTX 266,774 $13.0m4.18% 4.18% NewShares held: Q3 2024 0, Q4 2024 47.6k, Q1 2025 0, Q2 2025 266.8k
9 RHYTHM PHARMACEUTICALS INC COM RYTM RYTM 176,752 $11.2m3.60% 3.60% AddedShares held: Q3 2024 41.3k, Q4 2024 208.0k, Q1 2025 33.8k, Q2 2025 176.8k +142.9k +142,936 422.7%
10 ALKERMES PLC SHS ALKS ALKS 351,124 $10.0m3.23% 3.23% AddedShares held: Q3 2024 48.9k, Q4 2024 417.0k, Q1 2025 192.4k, Q2 2025 351.1k +158.8k +158,772 82.5%
11 DENALI THERAPEUTICS INC COM DNLI DNLI 707,915 $9.9m3.19% 3.19% AddedShares held: Q3 2024 282.1k, Q4 2024 584.3k, Q1 2025 667.1k, Q2 2025 707.9k +40.8k +40,837 6.1%
12 LEGEND BIOTECH CORP SPONSORED ADS LEGN LEGN 270,144 $9.6m3.09% 3.09% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 270.1k
13 GERON CORP COM GERN GERN 6,649,244 $9.4m3.02% 3.02% AddedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 960.3k, Q2 2025 6.6m +5.7m +5,688,937 592.4%
14 ZAI LAB LTD ADR ZLAB ZLAB 250,438 $8.8m2.82% 2.82% AddedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 26.4k, Q2 2025 250.4k +224.0k +224,017 847.9%
15 MINERALYS THERAPEUTICS INC COM MLYS MLYS 631,586 $8.6m2.75% 2.75% NewShares held: Q3 2024 0, Q4 2024 400.1k, Q1 2025 0, Q2 2025 631.6k
16 UNIQURE NV SHS QURE QURE 572,615 $8.0m2.57% 2.57% ReducedShares held: Q3 2024 0, Q4 2024 90.0k, Q1 2025 731.0k, Q2 2025 572.6k -158.4k -158,424 -21.7%
17 ROIVANT SCIENCES LTD SHS ROIV ROIV 601,781 $6.8m2.18% 2.18% ReducedShares held: Q3 2024 2.8m, Q4 2024 2.7m, Q1 2025 2.6m, Q2 2025 601.8k -2.0m -1,977,079 -76.7%
18 AKERO THERAPEUTICS INC COM AKRO AKRO 116,779 $6.2m2.01% 2.01% ReducedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 156.2k, Q2 2025 116.8k -39.4k -39,406 -25.2%
19 INSMED INC COM PAR $.01 INSM INSM 61,578 $6.2m2.00% 2.00% ReducedShares held: Q3 2024 0, Q4 2024 106.6k, Q1 2025 87.1k, Q2 2025 61.6k -25.5k -25,481 -29.3%
20 SURROZEN INC COM NEW SRZN SRZN 686,539 $6.1m1.98% 1.98% AddedShares held: Q3 2024 182.9k, Q4 2024 350.6k, Q1 2025 240.8k, Q2 2025 686.5k +445.7k +445,713 185.1%
21 WAVE LIFE SCIENCES LTD SHS 96663EUR 96663EUR 900,338 $5.9m1.88% 1.88% AddedShares held: Q3 2024 300.0k, Q4 2024 721.2k, Q1 2025 89.8k, Q2 2025 900.3k +810.5k +810,505 902.2%
22 LENZ THERAPEUTICS INC COM LENZ LENZ 183,912 $5.4m1.74% 1.74% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 183.9k
23 NUVALENT INC COM COM 59,828 $4.6m1.47% 1.47% ReducedShares held: Q3 2024 0, Q4 2024 145.2k, Q1 2025 190.4k, Q2 2025 59.8k -130.6k -130,573 -68.6%
24 KALVISTA PHARMACEUTICALS INC COM KALV KALV 386,790 $4.4m1.41% 1.41% ReducedShares held: Q3 2024 0, Q4 2024 992.8k, Q1 2025 386.8k, Q2 2025 386.8k -47 -47 -0.0%
25 VISTAGEN THERAPEUTICS INC COM VTGN VTGN 2,413,254 $4.1m1.33% 1.33% AddedShares held: Q3 2024 1.8m, Q4 2024 2.3m, Q1 2025 2.4m, Q2 2025 2.4m +46.7k +46,700 2.0%
26 APOGEE THERAPEUTICS INC COM COM 84,466 $3.7m1.18% 1.18% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 84.5k
27 IDEAYA BIOSCIENCES INC COM IDYA IDYA 165,885 $3.5m1.12% 1.12% AddedShares held: Q3 2024 132.7k, Q4 2024 0, Q1 2025 67.0k, Q2 2025 165.9k +98.9k +98,886 147.6%
28 PROTARA THERAPEUTICS INC COM STK TARA TARA 1,143,677 $3.5m1.12% 1.12% ReducedShares held: Q3 2024 942.9k, Q4 2024 332.4k, Q1 2025 1.2m, Q2 2025 1.1m -46.9k -46,902 -3.9%
29 HELIX ACQUISITION CORP II CL A ORD SHS BBOT BBOT 315,812 $3.3m1.06% 1.06% AddedShares held: Q3 2024 200.0k, Q4 2024 200.9k, Q1 2025 200.9k, Q2 2025 315.8k +114.9k +114,912 57.2%
30 EYEPOINT PHARMACEUTICALS INC COM NEW EYPT EYPT 329,254 $3.1m1.00% 1.00% NewShares held: Q3 2024 0, Q4 2024 579.5k, Q1 2025 0, Q2 2025 329.3k
31 ARCUTIS BIOTHERAPEUTICS INC COM ARQT ARQT 205,672 $2.9m0.93% 0.93% ReducedShares held: Q3 2024 1.8m, Q4 2024 501.0k, Q1 2025 440.1k, Q2 2025 205.7k -234.4k -234,401 -53.3%
32 REZOLUTE INC COM NEW RZLT RZLT 644,654 $2.9m0.93% 0.93% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 644.7k
33 TAYSHA GENE THERAPIES INC COM SHS TSHA TSHA 1,203,941 $2.8m0.90% 0.90% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 1.2m
34 NEWAMSTERDAM PHARMA COMPANY ORDINARY SHARES NAMS NAMS 152,652 $2.8m0.89% 0.89% AddedShares held: Q3 2024 0, Q4 2024 0, Q1 2025 104.6k, Q2 2025 152.7k +48.1k +48,067 46.0%
35 BIOHAVEN LTD COM BHVN BHVN 174,754 $2.5m0.79% 0.79% ReducedShares held: Q3 2024 216.4k, Q4 2024 186.4k, Q1 2025 250.6k, Q2 2025 174.8k -75.8k -75,810 -30.3%
36 REGENERON PHARMACEUTICALS COM REGN REGN 4,672 $2.5m0.79% 0.79% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 4.7k
37 BRIDGEBIO PHARMA INC COM BBIO BBIO 54,630 $2.4m0.76% 0.76% ReducedShares held: Q3 2024 94.9k, Q4 2024 0, Q1 2025 208.4k, Q2 2025 54.6k -153.8k -153,807 -73.8%
38 JANUX THERAPEUTICS INC COM JANX JANX 89,933 $2.1m0.67% 0.67% ReducedShares held: Q3 2024 49.4k, Q4 2024 145.9k, Q1 2025 342.1k, Q2 2025 89.9k -252.1k -252,129 -73.7%
39 ORIC PHARMACEUTICALS INC COM ORIC ORIC 200,785 $2.0m0.66% 0.66% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 200.8k
40 MBX BIOSCIENCES INC COM MBX MBX 141,021 $1.6m0.52% 0.52% AddedShares held: Q3 2024 50.0k, Q4 2024 0, Q1 2025 96.6k, Q2 2025 141.0k +44.4k +44,406 46.0%
41 PERCEPTIVE CAP SOLUTIONS COR CL A ORD SHS FRNM FRNM 150,000 $1.6m0.51% 0.51% UnchangedShares held: Q3 2024 150.0k, Q4 2024 150.0k, Q1 2025 150.0k, Q2 2025 150.0k
42 PRAXIS PRECISION MEDICINES I COM NEW PRAX PRAX 32,255 $1.4m0.44% 0.44% NewShares held: Q3 2024 174.0k, Q4 2024 134.2k, Q1 2025 0, Q2 2025 32.3k
43 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 100,826 $1.2m0.40% 0.40% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 100.8k
44 TANGO THERAPEUTICS INC COM TNGX TNGX 208,800 $1.1m0.34% 0.34% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 208.8k
45 PROTAGONIST THERAPEUTICS INC COM PTGX PTGX 16,770 $926.8k0.30% 0.30% ReducedShares held: Q3 2024 0, Q4 2024 141.7k, Q1 2025 49.2k, Q2 2025 16.8k -32.5k -32,471 -65.9%
46 TECTONIC THERAPEUTIC INC COM TECX TECX 40,000 $794.8k0.26% 0.26% NewShares held: Q3 2024 0, Q4 2024 9.4k, Q1 2025 0, Q2 2025 40.0k
47 ADC THERAPEUTICS SA SHS ADCT ADCT 283,286 $759.2k0.24% 0.24% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 283.3k
48 VERONA PHARMA PLC SPONSORED ADS VRNA VRNA 7,407 $700.6k0.23% 0.23% NewShares held: Q3 2024 0, Q4 2024 28.1k, Q1 2025 0, Q2 2025 7.4k
49 ABIVAX SA SPONSORED ADS ABVX ABVX 87,748 $671.3k0.22% 0.22% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 87.7k
50 MIND MEDICINE MINDMED INC COM NEW COM NEW 90,852 $589.6k0.19% 0.19% NewShares held: Q3 2024 0, Q4 2024 0, Q1 2025 0, Q2 2025 90.9k

Sold out since Q1 2025

SecurityTickerShares held beforeValue then
REVOLUTION MEDICINES INC RVMD RVMD 318,782 $11.3m318.8k shares
XENON PHARMACEUTICALS INC XENE XENE 274,633 $9.2m274.6k shares
CG ONCOLOGY INC CGON CGON 289,823 $7.1m289.8k shares
SPRINGWORKS THERAPEUTICS INC SWTX SWTX 159,305 $7.0m159.3k shares
CYTOKINETICS INC CYTK CYTK 149,648 $6.0m149.6k shares
BLUEPRINT MEDICINES CORP BPMC BPMC 61,927 $5.5m61.9k shares
EDGEWISE THERAPEUTICS INC EWTX EWTX 180,255 $4.0m180.3k shares
ENLIVEN THERAPEUTICS INC ELVN ELVN 120,430 $2.4m120.4k shares
NEUROCRINE BIOSCIENCES INC NBIX NBIX 21,052 $2.3m21.1k shares
ASCENDIS PHARMA A/S 14,732 $2.3m14.7k shares
SPYRE THERAPEUTICS INC SYRE SYRE 136,139 $2.2m136.1k shares
AMICUS THERAPEUTICS INC FOLD FOLD 268,919 $2.2m268.9k shares
ARBUTUS BIOPHARMA CORP ABUS ABUS 467,882 $1.6m467.9k shares
OCULAR THERAPEUTIX INC OCUL OCUL 124,523 $912.8k124.5k shares
DYNE THERAPEUTICS INC DYN DYN 84,430 $883.1k84.4k shares
SOLENO THERAPEUTICS INC SLNO SLNO 11,155 $797.0k11.2k shares
INFLARX NV IFRX IFRX 725,019 $739.5k725.0k shares
SOLID BIOSCIENCES INC SLDB SLDB 198,150 $733.2k198.2k shares
SIONNA THERAPEUTICS INC SION SION 60,000 $627.6k60.0k shares
BICARA THERAPEUTICS INC BCAX BCAX 47,078 $613.4k47.1k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
ROIVANT SCIENCES LTD ROIV · Call ROIVCall 915,000 $617.6k915.0k shares New
IMMUNOVANT INC IMVT · Call IMVTCall 100,000 $310.0k100.0k shares New
GERON CORP GERN · Call GERNCall 300,000 $52.5k300.0k shares New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
CELLECTAR BIOSCIENCES INC CLRB · 13G · filed 2026-08-14 CLRB 9.9%≈ $2.4m new 13G 2026-08-14
XILIO THERAPEUTICS INC XLO · 13G · filed 2026-08-14 XLO 9.5%≈ $5.8m 13G 2026-08-14
XILIO THERAPEUTICS INC 13G · filed 2026-02-17 8.4% +1.2 pts 13G 2026-02-17
SURROZEN INC SRZN · 13G · filed 2026-08-14 SRZN 5.0%≈ $15.6m +0.5 pts 13G 2026-08-14